ClinicalTrials.gg
RecruitingNCT06283979BLADE OPU2Updated Nov 10, 2026

A Randomized Controlled Phase II Trial of STIMULAN VG vs Standard of Care (SoC) for the Treatment of Osteomyelitis Associated With Stage IV Pressure Ulcers.

A Phase 2 interventional study of STIMULAN VG and Standard of Care in Pressure Ulcer, Stage IV and Osteomyelitis, sponsored by Biocomposites Ltd. Recruiting at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Biocomposites Ltd · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.
Updated Nov 10, 2026Primary completion movedStudy completion movedGo to Updates ↓
Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this trial is to assess the safety, tolerability and between-group effect size of STIMULAN VG (with debridement) and a course of systemic antibiotics to standard of care (debridement and systemic antibiotics only) for the treatment of osteomyelitis associated stage IV pressure ulcers.

Read the detailed description

The trial is an open-label, multi-center, randomized (1:1), controlled phase 2 trial in patients diagnosed with stage IV pressure ulcers.

02

Conditions studied

  • Pressure Ulcer, Stage IV
  • Osteomyelitis

Keywords

  • between-group effect size
  • surgical debridement
  • ulcer bursectomy
  • systemic antibiotics
03

In context

Pressure Ulcer

545 studies on the registry are indexed under Pressure Ulcer; 129 are open to participants now.

This study's planned enrollment of 60 is below the median of 70 across 405 interventional studies indexed under Pressure Ulcer.

Browse Pressure Ulcer studies →

Lead sponsor

Biocomposites Ltd is the lead sponsor of 4 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

In order to be eligible to participate in this study, subjects must meet all of the following criteria:

  1. Presenting with a Stage IV pressure ulcer requiring treatment of excision, bony debridement and flap coverage/primary closure.
  2. Operative candidate for flap surgery or primary closure.
  3. Presence of focal osteomyelitis as suggested by imaging to show extent of infection. Acceptable imaging techniques are Magnetic Resonance Imaging or CT scan.
  4. Adults ≥ 18 years in age at the time of treatment.
  5. Psychosocially, mentally, and physically able to fully comply with this protocol, including adhering to scheduled visits, treatment plan, completing forms, and other study procedures.
  6. Ability of the subject or legal authorized representative to provide voluntary, signed and dated prior to any study-related procedures.

Subjects who meet any of the following criteria will be excluded from participating in this study:

  1. Reasons contributing to pressure ulcer cannot be addressed.
  2. Severe immunological compromised patients as determined by the clinician.
  3. Patients with diffuse or widespread pelvic osteomyelitis that is not amenable to adequate margins for debridement.
  4. Patients presenting with head pressure ulcers.
  5. Current or recent history (within last 2 years) of active substance abuse (e.g., recreational drugs, narcotics, or alcohol) that in the judgement of the investigator, may compromise the participant's safety/recovery or ability to follow the trial procedures.
  6. Current smoker.
  7. Diabetic patient with level above 9.
  8. Allergy to any component of the product, such as calcium sulfate, glycopeptide antibiotics (Vancomycin), or aminoglycoside antibiotics (Gentamicin).
  9. Concurrent involvement in a study of another investigational product.
  10. Pregnant or planning to become pregnant during study period.
  11. Flexion contractures where patient cannot passively get full extension.
  12. Uncontrolled muscle spasms.
  13. Unable to comply with bedrest restriction or offloading requirements
  14. Unable to provide consent.
  15. Fecal or urinary incontinence with contamination of the wound.
  16. Lower extremity pressure ulcer location that is vascularly compromised as defined by an Ankle Brachial Index ≤ 0.7 mm Hg OR toe brachial index ≤ 0.6 mm OR toe pressure ≤ 40 mm Hg OR transcutaneous oximetry ≤ 40 mm Hg *
  17. Investigator considers the participant to be clinically malnourished.
  18. Any conditions with known hypercalcemia (> 10.3 mg/dl) or posing a significant risk for developing hypercalcemia (i.e., Hyperparathyroidism).
  19. Investigator believes trial participation may compromise safety of the participant or trial results.

    • Patients presenting with lower extremity pressure ulcers that are vascularly compromised can be rescreened followed successful revascularization
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Interventional STIMULAN VG

    Ulcer bursectomy and debridement and STIMULAN VG insertion into the ulcer cavity. Flap/primary closure. Peri-operative antibiotics.

    Combination Product: STIMULAN VG · Procedure: Standard of Care

  • Active comparator
    Standard of Care (SoC)

    Ulcer bursectomy, debridement and flap/primary closure. Peri-operative antibiotics.

    Procedure: Standard of Care

Interventions

  • Combination productSTIMULAN VG

    Insertion of STIMULAN VG into the ulcer cavity prior to flap/primary closure.

  • ProcedureStandard of Care

    Standard of Care. Ulcer bursectomy, debridement and flap/primary closure. Peri-operative antibiotics.

06

What researchers measure

Primary outcomes

  1. Individual patient success and findings at the 8 week follow-up visit

    An individual patient treatment will be considered a success if there is complete wound closure and healing at the surgical site at two consecutive visits 2 weeks apart.

    Time frame: 8 week

07

Study locations

9 of 9 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jun 2025 (actual). Primary completion is estimated for Aug 2027, 25 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Dec 2026 → Aug 2027 and completion Dec 2026 → Aug 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2024
First posted
Feb 28, 2024
StartActual
Jun 15, 2025
Primary completionEst.
Aug 1, 2027was Dec 2026
CompletionEst.
Aug 1, 2027was Dec 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 1, 2026→Aug 1, 2027
Nov 10, 2026
Study completion
Dec 1, 2026→Aug 1, 2027
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Primary completion Dec 1, 2026→Aug 1, 2027
    Study completion Dec 1, 2026→Aug 1, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06283979
Lead sponsor
Biocomposites Ltd
Collaborators
MCRA
Responsible party
Sponsor
First posted
Feb 28, 2024
Start date
Jun 15, 2025
Primary completion
Aug 1, 2027 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

Keira Watts, Clinical Research Director
Contact
clinicaltrials@biocomposites.com
+44 (0) 1782 338 580
Daniel Roberts
Contact
droberts@mcra.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion